Last $18.64 USD
Change Today +0.69 / 3.84%
Volume 1.1M
THRX On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Open
$18.10
Previous Close
$17.95
Day High
$18.68
Day Low
$17.63
52 Week High
02/19/14 - $32.88
52 Week Low
10/15/14 - $15.76
Market Cap
2.1B
Average Volume 10 Days
1.2M
EPS TTM
$-1.70
Shares Outstanding
115.0M
EX-Date
08/26/14
P/E TM
--
Dividend
$1.00
Dividend Yield
1.34%
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

241 Employees
Last Reported Date: 03/3/14
Founded in 1996

theravance inc (THRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.4K
Compensation as of Fiscal Year 2013.

theravance inc (THRX) Key Developments

Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer

Theravance Inc. announced the appointment of Eric d'Esparbes as Senior Vice President and Chief Financial Officer. Mr. d'Esparbes will report directly to Michael W. Aguiar, Chief Executive Officer, and be responsible for overseeing financial and IT operations of the company. Mr. d'Esparbes brings over 20 years of financial strategy and structuring, accounting and management experience to Theravance. Most recently Mr. d'Esparbes served as the Chief Financial Officer of Joule Unlimited, where he was responsible for overseeing all of the company's financial, tax, treasury and accounting activities.

Theravance Inc. Announces Management Resignations, Effective September 30, 2014

On September 16, 2014, Mathai Mammen, M.D., Ph.D. indicated that he will be resigning as Senior Vice President, Research and Development of Theravance Inc. effective September 30, 2014 in connection with his commencement of employment with Theravance Biopharma US Inc. On September 17, 2014, Leonard M. Blum indicated that he will be resigning as Senior Vice President and Chief Commercial Officer of the company effective September 30, 2014 in connection with his commencement of employment with Theravance Biopharma US Inc.

Theravance Inc. Announces Resignation of Bradford J. Shafer as Senior Vice President, General Counsel and Secretary

On August 21, 2014, Bradford J. Shafer indicated that he will be resigning as Senior Vice President, General Counsel and Secretary of Theravance Inc. effective August 31, 2014 in connection with his commencement of employment with Theravance Biopharma US Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $18.64 USD +0.69

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $13.15 USD +0.10
Nektar Therapeutics $12.64 USD -0.22
Progenics Pharmaceuticals Inc $4.70 USD -0.10
Sucampo Pharmaceuticals Inc $8.00 USD +0.06
Synergy Health PLC 1,776 GBp -6.00
View Industry Companies
 

Industry Analysis

THRX

Industry Average

Valuation THRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 878.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 437.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit www.theravance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.